Despite the hesitations of his sister ("Isn't quality of life far more important than quantity of life?"), it seemed as if he was even more determined to start adjuvant treatment. His physical condition had remarkably improved, and, after he had received further oral and written information on the specific treatment regimen from our oncology nurse, we decided to start chemotherapy.
To treat or not to treat: who should decide?
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Despite the hesitations of his sister ("Isn't quality of life far more important than quantity of life?"), it seemed as if he was even more determined to start adjuvant treatment. His physical condition had remarkably improved, and, after he had received further oral and written information on the specific treatment regimen from our oncology nurse, we decided to start chemotherapy. When I saw him after the first course of chemotherapy, he looked quite well. When I asked him about the past three weeks, however, he told me they had been awful. Mr C was in serious doubt: with respect to his chances of survival, he wanted to go for the maximum, but this reduction in quality of life was really not what he wanted. Although I could not pin down the exact toxicity he had experienced, the message was clear: he was not going to complete adjuvant chemotherapy in this way. For C was an aristocratic, 79-yearold Surinamese man. He visited my outpatient clinic because of a pT4aN1a colon carcinoma. After surgery, he went to a rehabilitation centre, but he was improving day by day and was determined to get home as soon as possible. Given his high-risk colon carcinoma, he had an indication for adjuvant chemotherapy with capecitabine and oxaliplatin. However, adjuvant chemotherapy could also hamper his rehabilitation process. Together we extensively discussed the pros and cons of adjuvant treatment. Afterward, Mr C seemed quite certain: the increased chances of living without cancer outweighed the risk of side-effects of chemotherapy. Nevertheless, I suggested he think it over and discuss the issue with his relatives. Two weeks later, Mr C came in again, accompanied by his sister.
Mr
Shared decision making is ethically sound and the evidence shows it leads to better outcomes. But if a patient is determined that they want no part in the decision, is it paternalistic to insist?
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The official journal of the Society for Translational Oncology a moment, I considered a dose reduction of oxaliplatin, but then decided to propose stopping oxaliplatin altogether. The added benefit of oxaliplatin to capecitabine in patients older than 70 may be limited, 1 and oxaliplatin presumably was the major cause of my patient's feelings of weakness and reduced walking ability. Also, I had the impression that the next course would be 'make or break'. If it did not go well, he would probably completely stop his adjuvant treatment, which would be a pity given his wish to go for the greatest chances of survival. Mr C and his family agreed to continue with capecitabine monotherapy.
I saw Mr C and his sister again four weeks later. In fact, he was one week late; he had accidentally extended his capecitabine-free period by one week. Nevertheless, he told me he felt terrible: he had lost weight and was using his cane to walk. He actively announced he wanted to reconsider chemotherapy. I asked him to step on the scales: 64 kg. This was exactly the same weight as when he started chemotherapy. Why then was Mr C telling me he had lost weight? And why did he complain about walking with a cane? He had been walking with a cane all the time! Again, Mr C reported side-effects of chemotherapy that I could not really confirm. How to continue? A dose reduction of capecitabine might help, but by extending his capecitabine-free period, Mr C had already effectively performed a form of capecitabine dose reduction. Was a further dose reduction going to help him? I did not think so. Wasn't Mr C actually telling me he wanted to stop the treatment? I asked him so. He denied tion with cancer patients.
2 Across cultures, different decision-making models can be identified, 3 but, as a doctor in the Netherlands, I have a legal obligation to inform my patient adequately about the pros and cons of a treatment, and I cannot start treatment without the patient's explicit consent. 4 Although some decisions concerning starting or stopping oncological treatment are clearly medically preferable (e.g. haematological grade 3 toxicity precludes continuation of chemotherapy), many decisions concern a clinical equipoise (i.e. options are equivalent and all appropriate). At this moment, both continuing and stopping adjuvant treatment could be considered appropriate for Mr C from a medical point of view. In such a case, the only adequate way to reach a decision seems to be through shared decision making. Apart from its ethical impetus, evidence indicates shared decision making improves patient outcomes.
5 So, why then did I not convince Mr C to share in the decision to stop his treatment? Should shared decision making sometimes be replaced by a doctor's decision if the patient chooses not to share in the decision making? Or… could the whole process we went through be called shared decision making after all?
Based on the degree of patient and doctor control, theorists have identified four prototypes (or quadrants) of doctor-patient interaction.
6-8 When doctor control is high and patient control is low, the relationship is characterised by 'paternalism', whereby the doctor controls the consultation agenda, and patients' values and preferences are not taken into account. For a long time, doctorpatient interactions could generally be characterised as paternalistic. If, in contrast, doctor control is low and patient control is high, one speaks of 'consumerism'. The patient sets the agenda and takes sole responsibility for the decision; the doctor's role is primarily one of information provider. In modern times, the societal image of a typical patient reflects such an autonomous, assertive, and well-informed consumer. If both patient and doctor control are low, a dysfunctional scenario of 'indecision or standstill' is at hand, and no decisions or this. Stopping was not really what he himself wanted to suggest. He wanted to know my expert opinion. I explained that in his case the choice to stop or to continue treatment was not just a medical decision but a decision that needed input from his side, too. Technically speaking, I had no formal reasons to stop adjuvant chemotherapy. Mr C was clinically well, laboratory results were within acceptable limits, and there were no grade 2 or higher toxicities, so if Mr C wanted to continue, we could continue. But Mr C insisted, "You are the expert". I paused for a moment. What was going on? Why did Mr C not simply tell me he wanted to stop, rather than insisting on my medical expertise? I decided to change gears and asked him how a decision to stop treatment would make him feel. When he swiftly responded, "Relieved," I simply made the decision to stop.
We talked a couple of minutes more about the logistics of follow-up. Then, Mr C and his sister left the room -relieved.
I stayed behind -confused and irritated. Why had I made this decision when I feel so strongly that this kind of decision making should be shared between a doctor and a patient? Being trained in the age of patient's autonomy and rights, shared decision making is a natural part of my consulta-"Why had I made this decision when I feel so strongly that this kind of decision making should be shared?"
ONCOLOGIST AND PATIENT STRUGGLING TO MAKE A DECISION progress can be made. Finally, if both patient and doctor have high control, this represents 'mutuality' or a 'shared' model. The agenda is set jointly, patients are told that there are equivalent options, appropriate information is given based on the doctor's expertise, the patient's values and preferred role in decision making are explored, and eventually both parties are satisfied with the decision-making process and the eventual decision. 5, 9 This is the prototype of the doctor-patient input that reflects shared decision making, as currently advocated. 10 Clearly, in the case of Mr C, 'consumerism' was not an issue. Having the consultation ending in 'indecision' was not an option as, in contrast to palliative treatment, in adjuvant treatment the time frame is stringent. Despite my preferred 'shared and mutual' decision-making style, I felt as if I had ended up in the 'paternalistic' quadrant. Although Mr C had set the agenda to discuss the continuation of chemotherapy, and I had explored his values and preferences, in the end I made the final decision, and the ownership of that decision was shifted to my side. However, paradoxically, in a way, in the case of Mr C, shared decision making would have been paternalistic too, as I would have forced him into taking responsibility for a decision from which he seemed to want to defer.
Why was it so difficult for Mr C to share in the responsibility for the final decision? Several barriers to shared decision making can be identified from the literature that may be categorised into the following: a 'lack of competencies' required to take part in the decision-making process; a 'position of dependency' in the patient-doctor relationship, hampering active involvement in decision making; and the 'inability to cope' with the burden of decision making. The modern focus on patient-centred communication requires a high level of communication competence from the care provider but also from the patient. Patients need competencies enabling them to ask questions, act assertively, and express their concerns and feelings.
11 It was shown that less-educated patients more often prefer a passive role in decision making.
12 Also, an exploratory study showed that lay people's confidence in their understanding of cancer-related jargon was related to their perceived efficacy in participating in treatment decision making with a fictive oncologist. 13 Moreover, patients mention barriers to participation such as simply forgetting questions or not knowing how to interrupt the doctor. 14 Mr C, however, was a well-educated, eloquent man, and competence may not have been a major issue. Possibly the second barrier -dependency in 
